Orion secures EU orphan designation for Hippo pathway-targeted ODM-212 in mesothelioma

Edited by Robert McTiernan··3 min read

Finland-based Orion Oyj (Helsinki: ORNBV) announced receipt of orphan designation from the European Commission for ODM-212 in malignant mesothelioma, based on a positive recommendation from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).

In the EU, orphan drug designation provides a 10-year period of marketing exclusivity following product approval, along with incentives including protocol assistance from the EMA and direct access to the centralized authorization procedure.

The EC designation follows an FDA orphan drug designation granted to ODM-212 for mesothelioma in April 2026, giving Orion Pharma regulatory recognition in both major jurisdictions for a cancer with limited approved treatment options beyond first-line chemotherapy and immunotherapy.

ODM-212 is an oral small-molecule pan-TEAD (Transcriptional Enhanced Associate Domain) inhibitor that targets the Hippo signaling pathway. The compound blocks TEAD transcription factors, disrupts YAP-TEAD protein-protein interactions, and inhibits TEAD auto-palmitoylation — a post-translational modification required for TEAD activity. Dysregulation of the Hippo pathway, particularly through YAP/TAZ activation, has been associated with uncontrolled tumor growth and resistance to existing cancer therapies.

ODM-212 is being evaluated in the Phase I/II TEADES trial (NCT06725758) in patients with malignant pleural mesothelioma (MPM), epithelioid hemangioendothelioma (EHE), and other solid tumors with Hippo pathway dysfunction who have progressed after standard treatments. Phase I data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May reported an overall response rate (ORR) of 27.8% and a disease control rate (DCR) of 77.8% in mesothelioma patients. The Phase II portion of TEADES is enrolling up to 300 patients. Orion has also initiated the TEADCO Phase Ib/II basket trial, which evaluates ODM-212 in combination with standard-of-care treatments across advanced mesothelioma, KRAS G12C-mutated non-small cell lung cancer (NSCLC), and pancreatic cancer.

The AllSci BriefSystematic R&D and deal news. Daily.

The TEAD inhibitor space has attracted increasing competitive interest. San Mateo, California-based Vivace Therapeutics has advanced VT3989, a TEAD autopalmitoylation inhibitor that received FDA orphan drug designation for mesothelioma in July 2025. Phase I/II data for VT3989 reported at the European Society for Medical Oncology (ESMO) Congress 2025 demonstrated an ORR of 32%, a DCR of 86%, and median progression-free survival of 40 weeks in refractory mesothelioma patients, with Vivace stating plans to advance VT3989 into a Phase III registrational trial. Both ODM-212 and VT3989 target TEAD autopalmitoylation as a core mechanism, though Orion describes ODM-212 as a pan-TEAD inhibitor with a broader mechanistic profile that additionally disrupts YAP-TEAD protein-protein interactions.

Malignant mesothelioma is a rare and aggressive cancer primarily affecting the pleural lining of the lungs, strongly associated with asbestos exposure. Median survival following diagnosis has historically been approximately one year. Current standard-of-care in the first-line setting includes platinum-based chemotherapy with pemetrexed and, more recently, the combination of ipilimumab and nivolumab. There are no approved targeted therapies specifically addressing Hippo pathway dysregulation, which is characteristic of a substantial proportion of mesothelioma cases.

The EC designation applies specifically to malignant mesothelioma, while the broader TEADES trial encompasses MPM, EHE, and other Hippo pathway-dysregulated solid tumors — a scope that may support future label expansion discussions if efficacy data mature across multiple tumor types.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/